Research Papers

25 of 2264 papers

CSV Excel
Quick filters: Open Data Open Code Pre-registered Funding Declared COI Declared Open Access Clear Filters
Path towards mRNA delivery for cancer immunotherapy from bench to bedside.
Chen W; Zhu Y; He J; Sun X.
Theranostics (Unknown)
Published: 2024
3/6 Transparent
Funding Declared
Inactivation of ERK1/2 signaling mediates dysfunction of basal meningeal lymphatic vessels in experimental subdural hem…
Yuan J; Liu X; Nie M; Chen Y; Liu M; Huang J; Jiang W; Gao C; Quan W; Gong Z; Xiang T; Zhang X; Sha Z; Wu C; Wang D; Li S; Zhang J; Jiang R.
Theranostics (Unknown)
Published: 2024
3/6 Transparent
Funding Declared
Bile acid-containing lipid nanoparticles enhance extrahepatic mRNA delivery.
Patel SK; Billingsley MM; Mukalel AJ; Thatte AS; Hamilton AG; Gong N; El-Mayta R; Safford HC; Merolle M; Mitchell MJ.
Theranostics (Unknown)
Published: 2024
3/6 Transparent
Funding Declared
Endosialin in Cancer: Expression Patterns, Mechanistic Insights, and Therapeutic Approaches.
Lu S; Gan L; Lu T; Zhang K; Zhang J; Wu X; Han D; Xu C; Liu S; Yang F; Qin W; Wen W.
Theranostics (Unknown)
Published: 2024
3/6 Transparent
Funding Declared
Visualizing vasculature and its response to therapy in the tumor microenvironment.
Lin Q; Choyke PL; Sato N.
Theranostics (Unknown)
Published: 2023
2/6 Transparent
1α,25(OH)<sub>2</sub>D<sub>3</sub> ameliorates insulin resistance by alleviating γδ T cell inflammation via enhancing f…
Li P; Li K; Yuan W; Xu Y; Li P; Wu R; Han J; Yin Z; Lu L; Gao Y.
Theranostics (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Upregulated FOXM1 stimulates chondrocyte senescence in Acot12<sup>-/-</sup>Nudt7<sup>-/-</sup> double knockout mice.
Song J; Kim EH; Yang JH; Kim D; Robby AI; Kim SA; Park SY; Ryu JH; Jin EJ.
Theranostics (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Inhalation of acidic nanoparticles prevents doxorubicin cardiotoxicity through improvement of lysosomal function.
Santin Y; Formoso K; Haidar F; Fuentes MDPO; Bourgailh F; Hifdi N; Hnia K; Doghri Y; Resta J; Champigny C; Lechevallier S; Détrait M; Cousin G; Bisserier M; Parini A; Lezoualc'h F; Verelst M; Mialet-Perez J.
Theranostics (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Fe(III)-Shikonin supramolecular nanomedicines as immunogenic cell death stimulants and multifunctional immunoadjuvants …
Feng W; Shi W; Cui Y; Xu J; Liu S; Gao H; Zhu S; Liu Y; Zhang H.
Theranostics (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Theranostics with photodynamic therapy for personalized medicine: to see and to treat.
Wang Y; Staudinger JN; Mindt TL; Gasser G.
Theranostics (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Aptamer-engineered (nano)materials for theranostic applications.
Rabiee N; Chen S; Ahmadi S; Veedu RN.
Theranostics (Unknown)
Published: 2023
2/6 Transparent
The role of radiolabeling in BNCT tracers for enhanced dosimetry and treatment planning.
Mushtaq S; Ae PJ; Kim JY; Lee KC; Kim KI.
Theranostics (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Photocurable injectable Janus hydrogel with minimally invasive delivery for all-in-one treatment of gastric perforation…
Wu X; Wang Z; Xu J; Yu L; Qin M; Li J; Liu S; Zheng W; Li Z; Ouyang J; Li Y; Li G; Wang L; Huang W; Wu Y.
Theranostics (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Tet1 deficiency exacerbates oxidative stress in acute kidney injury by regulating superoxide dismutase.
Fan Y; Yuan Y; Xiong M; Jin M; Zhang D; Yang D; Liu C; Petersen RB; Huang K; Peng A; Zheng L.
Theranostics (Unknown)
Published: 2023
4/6 Transparent
Data Funding Declared
Engineered oncolytic bacteria HCS1 exerts high immune stimulation and safety profiles for cancer therapy.
Sun Y; Guo Y; Liu X; Liu J; Sun H; Li Z; Wen M; Jiang SN; Tan W; Zheng JH.
Theranostics (Unknown)
Published: 2023
4/6 Transparent
Data Funding Declared
Engineering CAR-T cells for radiohapten capture in imaging and radioimmunotherapy applications.
Kurtz K; Eibler L; Dacek MM; Carter LM; Veach DR; Lovibond S; Reynaud E; Qureshy S; McDevitt MR; Bourne C; Monette S; Punzalan B; Khayat S; Verma S; Kesner AL; Cheung NV; Schöder H; Gajecki L; Cheal SM; Larson SM; Scheinberg DA; Krebs S.
Theranostics (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
A genome-wide CRISPR/Cas9 screen identifies DNA-PK as a sensitiser to <sup>177</sup>Lutetium-DOTA-octreotate radionucli…
Waldeck K; Van Zuylekom J; Cullinane C; Gulati T; Simpson KJ; Tothill RW; Blyth B; Hicks RJ.
Theranostics (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Advanced hitchhiking nanomaterials for biomedical applications.
Wang Y; Sun SK; Liu Y; Zhang Z.
Theranostics (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Oral [60]fullerene reduces neuroinflammation to alleviate Parkinson's disease via regulating gut microbiome.
Li X; Deng R; Li J; Li H; Xu Z; Zhang L; Feng L; Shu C; Zhen M; Wang C.
Theranostics (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Targeted elimination of senescent cells by engineered extracellular vesicles attenuates atherosclerosis in ApoE<sup>-/-…
Zhang L; Wang C; Hu W; Bu T; Sun W; Zhou T; Qiu S; Wei M; Xing H; Li Z; Yang G; Yuan L.
Theranostics (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
3D autofluorescence imaging of hydronephrosis and renal anatomical structure using cryo-micro-optical sectioning tomogr…
Fan G; Jiang C; Huang Z; Tian M; Pan H; Cao Y; Lei T; Luo Q; Yuan J.
Theranostics (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
5-aminolevulinate and CHIL3/CHI3L1 treatment amid ischemia aids liver metabolism and reduces ischemia-reperfusion injur…
Jin G; Guo N; Liu Y; Zhang L; Chen L; Dong T; Liu W; Zhang X; Jiang Y; Lv G; Zhao F; Liu W; Hei Z; Yang Y; Ou J.
Theranostics (Unknown)
Published: 2023
4/6 Transparent
Data Funding Declared
Discovery of a novel NAMPT inhibitor that selectively targets NAPRT-deficient EMT-subtype cancer cells and alleviates c…
Kim M; Kim H; Kang BG; Lee J; Kim T; Lee H; Jung J; Oh MJ; Seo S; Ryu MJ; Sung Y; Lee Y; Yeom J; Han G; Cha SS; Jung H; Kim HS.
Theranostics (Unknown)
Published: 2023
4/6 Transparent
Data Funding Declared
Phase I clinical evaluation of <sup>99m</sup>Tc-labeled Affibody molecule for imaging HER2 expression in breast cancer.
Bragina O; Chernov V; Larkina M; Rybina A; Zelchan R; Garbukov E; Oroujeni M; Loftenius A; Orlova A; Sörensen J; Frejd FY; Tolmachev V.
Theranostics (Unknown)
Published: 2023
4/6 Transparent
Registered Funding Declared
Blocking Tim-3 enhances the anti-tumor immunity of STING agonist ADU-S100 by unleashing CD4<sup>+</sup> T cells through…
Luo J; Pang S; Hui Z; Zhao H; Xu S; Yu W; Yang L; Sun Q; Hao X; Wei F; Wang J; Ren X.
Theranostics (Unknown)
Published: 2023
3/6 Transparent
Funding Declared